Mobile Site ›
Print Friendly View

Test ID: BCLL    
IGH for B-Cell Chronic Lymphocytic Leukemia (B-CLL), Somatic Hypermutation Analysis

Useful For Suggests clinical disorders or settings where the test may be helpful

Prognostic information in patients with newly diagnosed B-cell chronic lymphocytic leukemia

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

B-cell chronic lymphocytic leukemia (B-CLL) has a very variable prognosis and no single clinical or laboratory feature accurately predicts prognosis in individual patients at this time. Thus, a group of prognostic features are used. One of the best prognostic indicators is the presence or absence of somatic hypermutation within the immunoglobulin heavy chain gene (IGH) variable (V) region of the neoplastic clone.

 

Each mature B cell contains 2 IGH alleles, and 1 or both may have undergone rearrangement from the germ line state during the antigen-independent stage of normal B-cell development. It is generally believed that only a single functional rearrangement (ie, able to make a functional immunoglobulin heavy chain protein) is transcribed, although the other allele may contain a nonfunctional rearrangement. The rearranged gene contains, as contiguous components, a leader sequence, a variable (V) segment, and a diversity (D) segment. A noncontiguous constant (C) segment is also present.

 

Some B cells also undergo the antigen-dependent mutation process termed somatic hypermutation, which introduces point mutations into the V region. Patients with clones carrying unmutated IGH V region rearrangements are associated with a significantly worse prognosis than patients with clones carrying mutated IGH V region rearrangements. This finding is based on survival curve data in which 2% or greater mutation frequency in the complete V region of a functional IGH rearrangement was used as the criteria for mutated status. In 2 large studies, patients with unmutated status had a median survival of approximately 9 years, while those with mutated status had a median survival of at least 20 years.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretive report will be provided.

Interpretation Provides information to assist in interpretation of the test results

The presence or absence of somatic hypermutation in the immunoglobulin heavy chain gene (IGH) variable (V) region DNA will be reported. A mutation frequency of 2% or greater will be reported as mutated. Both the percent mutation and the V region allele identified in the rearrangement will be included in the report.

 

B-cell chronic lymphocytic leukemia (B-CLL) lacking somatic hypermutation of the IGH V region (unmutated) is associated with a significantly worse prognosis than B-CLL containing somatic hypermutation of the IGH V region (mutated).

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

The prognostic significance of somatic hypermutation status is only known when a single functional IGH rearrangement is identified. However, a variety of situations can occur, for which the clinical significance is unknown at this time. These can broadly be grouped into the following:

1. Greater than 1 functional rearrangement is identified, with discordant mutation status

2. Only nonfunctional rearrangements are identified

 

Rearrangements with mutation status at or near the 2% cutoff should be interpreted with caution for the purposes of prognosis, particularly if the entire IGH V sequence could not be sequenced due to the use of V region primers. Neoplasms with this type of result will be identified by a comment in the report.

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

1. Hamblin TJ, Davis Z, Gardiner A, et al: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999 September 15;94(6):1848-1854

2. Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999 September 15;94(6):1840-1847

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test